Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in the Eurasian Economic Union (EAEU) has been showing a steady growth in recent years.
Customer preferences: The growing prevalence of viral infections has led to an increase in demand for antiviral drugs in the EAEU region. The customers in the region are increasingly opting for antiviral drugs due to their effectiveness in treating viral infections such as influenza, HIV, and hepatitis. The customers are also showing a preference for combination antiviral therapies, which offer a higher efficacy rate and reduce the chances of viral resistance.
Trends in the market: Russia is the largest market for antiviral drugs in the EAEU region, followed by Kazakhstan and Belarus. The market is dominated by a few major players, who have a strong presence in the region. The trend in the market is towards the development of new antiviral drugs that are more effective and have fewer side effects. The market players are also focusing on the development of combination therapies that can treat multiple viral infections.
Local special circumstances: The EAEU region has a high prevalence of viral infections, which has led to a high demand for antiviral drugs. The region also has a large population, which provides a large customer base for the market players. However, the market players have to deal with a complex regulatory environment, which can make it difficult to bring new drugs to the market. The market players also have to deal with the issue of counterfeit drugs, which can reduce the trust of customers in the market.
Underlying macroeconomic factors: The growth of the Antiviral Drugs market in the EAEU region is driven by several macroeconomic factors. The region has a growing middle class, which has increased the demand for healthcare services, including antiviral drugs. The region also has a high prevalence of viral infections, which has led to a high demand for antiviral drugs. The governments in the region are also investing in healthcare infrastructure, which is expected to drive the growth of the market in the future. The market players in the region are also investing in research and development, which is expected to lead to the development of new and more effective antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
